A Phase III Trial of Surgery With or Without Adjunctive External Pelvic Radiation Therapy in Intermediate-Risk Endometrial Adenocarcinoma: A Gynecologic Oncology Group Study

Receipt of vaginal brachytherapy is associated with improved survival in women with stage I endometrioid adenocarcinoma of the uterus: A National Cancer Data Base study

“…Gynecologic Oncology Group trial 99 en-rolled women with stage I or occult stage II endometrial cancer who had undergone TAH-BSO and lymph node dissection and randomized them to pelvic RT or observation. 2 The addition of pelvic RT reduced the cumulative incidence of LRR at 2 years from 12% to 3%. In a subset of patients defined as high-to intermediate-risk (HIR), this benefit was larger, with the 2-year LRR rate reduced from 26% to 6%.…”

“…In this Original Article analysis, both older age and higher histologic grade were associated with increased mortality; these findings mirror the results of multiple prospective series. 2,7,8 In addition, a larger tumor size was also associated with increased mortality. This supports historical single-institution series, which suggested the prognostic importance of tumor size.…”

“…16 It is also notable that the majority of pelvic recurrences occur within the vaginal cuff. 2,3,17 For this reason, the PORTEC-2 trial enrolled women with stage IA, grade 3 or stage IB, grade 1/2 endometrial cancer treated with TAH-BSO and randomized them to pelvic RT or VB. 18 There was no difference in LRR or OS between the arms, although pelvic RT yielded a statistically significant reduction in the low rate of nonvaginal pelvic failures.…”

Current recommendations and recent progress in endometrial cancer

“…Intermediate-risk disease is described by a wide body of literature, including at least 6 randomized trials. [89][90][91][92][93][94] Intermediate risk is typically defined as having any MMI, up to occult stage II disease, or grade 2 or 3 disease. A subgroup of high-intermediate risk (HIR) has also been defined by the GOG and the Post-Operative Radiation Therapy in Endometrial Cancer (PORTEC) group.…”

A Molecular Carrier to Transport and Deliver Cisplatin into Endometrial Cancer Cells

“…Survival is directly related to the surgical stage, and the role of adjuvant radiotherapy in EC remains controversial. Several studies have demonstrated that external pelvic radiotherapy reduces isolated local recurrence (5,6), while adjuvant chemotherapy is recommended for patients with advanced disease; its combination with radiotherapy is still under debate (7). Platinum (Pt) compounds, anthracyclines, and more recently taxanes have been used alone or in combination regimens, achieving response rates exceeding 50% and resulting in more than 1-year survival in randomized trials (8)(9)(10)(11)(12)(13)(14).Toxicity is a crucial point in this process, especially when associated with advanced age and multiple comorbidities.…”